Tyck till om SwePub Sök
här!
Sökning: onr:"22096961" >
Prognostic nomogram...
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
-
Lee, C.K. (författare)
-
Simes, R.J. (författare)
-
Brown, C. (författare)
-
visa fler...
-
Lord, S. (författare)
-
Wagner, U. (författare)
-
Plante, M. (författare)
-
Vergote, I. (författare)
-
Pisano, C. (författare)
-
Parma, G. (författare)
-
Burges, A. (författare)
-
Bourgeois, H. (författare)
-
Hogberg, T. (författare)
-
Bentley, J. (författare)
-
Angleitner-Boubenizek, L. (författare)
-
Ferrero, A. (författare)
-
Richter, B. (författare)
-
Hirte, H. (författare)
-
Gebski, V. (författare)
-
Pfisterer, J. (författare)
-
Pujade-Lauraine, E. (författare)
-
Friedlander, M. (författare)
-
visa färre...
-
(utgivare)
- Cancer Research UK 2011
- 2011
- Engelska.
-
Ingår i: British Journal of Cancer. - 0007-0920. ; 105:8, 1144-1150
Abstract
Ämnesord
Stäng
- BACKGROUND: Patients with platinum-sensitive recurrent ovarian cancer are a heterogeneous group, and it is not possible to accurately predict the progression-free survival (PFS) in these patients. We developed and validated a nomogram to help improve prediction of PFS in patients treated with platinum-based chemotherapy. METHODS: The nomogram was developed in a training cohort (n = 955) from the CALYPSO trial and validated in the AGO-OVAR 2.5 Study (n = 340). The proportional-hazards model (nomogram) was based on pre-treatment characteristics. RESULTS: The nomogram had a concordance index (C-index) of 0.645. Significant predictors were tumour size platinum-chemotherapy-free interval, CA-125, number of organ metastatic sites and white blood count. When the nomogram was applied without CA-125 (CA-125 was not available in validation cohort), the C-indices were 0.624 (training) and 0.594 (validation). When classification was based only on the platinum-chemotherapy-free interval, the indices were 0.571 (training) and 0.560 (validation). The calibration plot in the validation cohort based on four predictors (without CA-125) suggested good agreement between actual and nomogram-predicted 12-month PFS probabilities. CONCLUSION: This nomogram, using five pre-treatment characteristics, improves prediction of PFS in patients with platinum-sensitive ovarian cancer having platinum-based chemotherapy. It will be useful for the design and stratification of patients in clinical trials and also for counselling patients.
Ämnesord
- Medical and Health Sciences (hsv)
- Medicin och hälsovetenskap (hsv)
- MEDICINE (svep)
- MEDICIN (svep)
Nyckelord
- nomogram; recurrent ovarian cancer; prognosis; platinum sensitivity; progression-free survival
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Lee, C.K.
-
Simes, R.J.
-
Brown, C.
-
Lord, S.
-
Wagner, U.
-
Plante, M.
-
visa fler...
-
Vergote, I.
-
Pisano, C.
-
Parma, G.
-
Burges, A.
-
Bourgeois, H.
-
Hogberg, T.
-
Bentley, J.
-
Angleitner-Boube ...
-
Ferrero, A.
-
Richter, B.
-
Hirte, H.
-
Gebski, V.
-
Pfisterer, J.
-
Pujade-Lauraine, ...
-
Friedlander, M.
-
visa färre...
- Av lärosätet
-
Swepub_uni:_t